Overview

A Pilot Study of Ipilumimab and Radiation in Poor Prognosis Melanoma

Status:
Completed
Trial end date:
2018-09-01
Target enrollment:
Participant gender:
Summary
This is a pilot study assessing the safety of the combination of ipilimumab administered concurrently with radiotherapy for patients with locally advanced or unresectable melanoma and patients at high risk for recurrence after resection.
Phase:
Phase 1
Details
Lead Sponsor:
Duke University